FMP 2.1 malaria vaccine

Drug Profile

FMP 2.1 malaria vaccine

Alternative Names: FMP2.1/AS02A; FMP 2.1-AS02A-malaria-vaccine; FMP2.1; FMP2.1 vaccine

Latest Information Update: 25 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator United States Army Medical Research and Materiel Command; Walter Reed Army Institute of Research
  • Developer GlaxoSmithKline; National Institute of Allergy and Infectious Diseases; United States Army Medical Research and Materiel Command; University of Maryland, Baltimore; Walter Reed Army Institute of Research
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 25 Jun 2015 Discontinued - Phase-I for Malaria (In children, In infants, Prevention) in Mali (IM)
  • 25 Jun 2015 Discontinued - Phase-I for Malaria (Prevention) in Mali (IM)
  • 25 Jun 2015 Discontinued - Phase-I/II for Malaria (Prevention) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top